Mateon Provides Corporate Update and Reports Third Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Mateon Provides Corporate Update and Reports Third Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq: MATN ), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the third quarter of 2016.

Recent Corporate Highlights

  • Entered into a collaboration with U.S. Oncology Research for their participation in Mateon’s Phase 2/3 FOCUS Study evaluating CA4P in combination with bevacizumab (Avastin®) and chemotherapy for the treatment of patients with platinum-resistant ovarian cancer.
  • Continued to expand the number of U.S. investigator sites participating in the FOCUS Study.
  • Expanded the FOCUS Study into Europe, with sites in Belgium now actively recruiting patients.
  • Completed enrollment in the second cohort and initiated the third cohort of OX1222, an open-label dose-ranging study of OXi4503 in combination with cytarabine, in patients with relapsed/refractory acute myeloid leukemia (AML).
  • Received an issued patent for pre-clinical cathepsin-inhibiting compounds from the U.S. Patent and Trademark Office.
  • Expanded Board of Directors with appointment of two experienced biopharmaceutical executives.

“I am pleased that our most advanced clinical trial, the FOCUS Study, remains on track and now has 20 investigator sites qualified to enroll patients,” stated William D. Schwieterman, M.D., Mateon’s President and Chief Executive Officer. “Importantly, we are seeking to demonstrate improvement over the current standard of care in platinum-resistant ovarian cancer, and positive results from this trial could ultimately change the treatment paradigm in ovarian cancer, as well as the much broader field of vascular-targeted therapy in a variety of other solid tumor cancers. Therefore, the results of this clinical trial are critical to our goal of creating long-term shareholder value.”

Financial Results for the Third Quarter of 2016

For the third quarter of 2016, Mateon reported a net loss of $3.2 million compared to a net loss of $3.6 million for the third quarter of 2015. R&D expenses decreased to $2.1 million in the third quarter of 2016, compared to $2.5 million in the third quarter of 2015, while general and administrative expenses increased to $1.2 million for the third quarter of 2016 compared to $1.1 million for the third quarter of 2015.

At September 30, 2016, Mateon had cash, cash equivalents and short-term investments of $16.3 million, which the Company currently believes is sufficient to fund operations through the availability of key clinical data from the FOCUS Study, which is expected in the second half of 2017.

About Mateon Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.

At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.

Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide. 

Safe Harbor Statement This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, data and regulatory guidance relative to our clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions Mateon might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development, manufacturing and regulatory review, and the availability of additional financing to pursue and continue development of our programs. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Mateon’s reports to the Securities and Exchange Commission, including Mateon’s reports on Form 10-K, 10-Q and 8-K. However, Mateon undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

                 
Mateon Therapeutics, Inc.                
Statement of Operations Data                
(Unaudited)                
      Three months ended September 30,       Nine months ended September 30,  
      2016       2015       2016       2015  
                                 
    (all amounts in thousands, except per share data)
Operating Expenses:                
Research and development   $ 2,075     $ 2,457     $ 6,429     $ 6,107  
General and administrative     1,187       1,142       3,855       3,597  
                 
Total operating expenses     3,262       3,599       10,284       9,704  
                 
Loss from Operations     (3,262 )     (3,599 )     (10,284 )     (9,704 )
                 
Interest income     26       7       84       15  
Other income (expense), net     -       -       (1 )     1  
                 
Net loss and comprehensive loss   $ (3,236 )   $ (3,592 )   $ (10,201 )   $ (9,688 )
                 
Basic and diluted net loss per common share                
attributable to common stock   $ (0.12 )   $ (0.14 )   $ (0.38 )   $ (0.39 )
Weighted-average number of common shares                
outstanding     26,545       26,545       26,545       24,748  
                 
Mateon Therapeutics, Inc.        
Balance Sheet Data        
(Unaudited)        
    September 30, 2016   December 31, 2015
                 
    (all amounts in thousands)
  Assets          
         
Cash and cash equivalents   $ 5,167     $ 27,285  
Short-term investments     11,113       -  
Prepaid expenses and other current assets     934       105  
Other assets     47       63  
         
Total assets   $ 17,261     $ 27,453  
         
  Liabilities and stockholders' equity        
         
Accounts payable and accrued liabilities   $ 1,485     $ 2,103  
Total stockholders' equity     15,776       25,350  
         
Total liabilities and stockholders' equity   $ 17,261     $ 27,453  
         

CONTACTS Investors: ir@mateon.com 650-635-7000 Media: JPA Health Communications Nic DiBella nic@jpa.com 617-945-5183

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 42

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 569

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 101

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 94

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 81

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 42

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 17

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 103

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
tion End -->

Top 5 Most Recently Viewed Articles

Mountain Lake Lodge Unveils Exciting 2026 Dance Weekend

Updated Category News Views 875

Virginia's Mountain Lake Lodge Reveals New Weekend Events For fans of the classic film Dirty Dancing, Virginia's Mountain Lake Lodge offers a chance to revisit a piece of cinematic history. As the original filming location, the lodge is thrilled to announce its much-anticipated Dirty Dancing Weekend schedule for 2026, along with plans for the upcoming Summer Festival....

Continue Reading
Regenx Tech Faces Audit Delays and Seeks Management Cease Order

Updated Category News Views 241

Regenx Tech Corporation Faces Filing Delays Regenx Tech Corp, known for pioneering technology in the recycling of end-of-life diesel catalytic converters, is currently navigating through challenges with its annual financial filings. The company, which operates under the ticker symbols CSE: RGX, OTCQB: RGXT, and Frankfurt: YRS, announced that due to delays in completing...

Continue Reading
Foresight Mental Health Launches Innovative Maternal Support Program

Updated Category News Views 133

Foresight Mental Health Launches Innovative Support Program Foresight Mental Health is excited to unveil its groundbreaking Maternal Mental Health Program, a comprehensive initiative aimed at providing expert mental health support across various stages of the reproductive journey. This program is particularly focused on addressing the substantial unmet needs of birthing...

Continue Reading
Navigating Market Uncertainty with Financial Planning

Updated Category News Views 125

Staying Calm Amid Market Chaos The market's like a roller coaster more often than not, and when headlines scream panic, even the most seasoned of us can begin to doubt our strategies. Jennifer Prosise from The Voyager Group, Ltd., in Joliet, IL, calls out this high-stakes game in HelloNation, emphasizing how financial planning serves as our anchor in the stormy seas of...

Continue Reading
Yondr Group Expands with New 550MW Data Center in Dallas

Updated Category News Views 458

Yondr Group's Ambitious Move in the US Market Yondr Group, renowned for its innovative advancements in data center development, has embarked on a groundbreaking project that promises to accelerate its growth in the competitive US market. The company recently acquired a significant 163-acre site near Dallas, Texas, which is set to become home to a massive data center...

Continue Reading